Cover Image

Incretin‐based therapy and the risk of diabetic foot ulcers and related events

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Nikki C. C. Werkman, Johanna H. M. Driessen, Olaf H. Klungel, Nicolaas S. Schaper, Patrick C. Souverein, Coen D. A. Stehouwer, Johannes T. H. Nielen
Format:	Artículo Open Access
Published:	Wiley 2024
Subjects:	Diabetes, Obesity and Metabolism
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

The association of type 2 diabetes‐related characteristics with fracture risk at different sites
by: Veerle van Hulten, et al.
Published: (2024)

Prediction of glycaemic control and quality of life in people with type 2 diabetes using glucose‐lowering drugs with machine learning—The Maastricht study
by: Nikki C. C. Werkman, et al.
Published: (2025)

Hydrogel dressings for diabetic foot ulcer: A systematic review and meta‐analysis
by: Hongjiao Zhao, et al.
Published: (2024)

Incretin mimetics for weight loss forgive nonadherence
by: Anıl Cengiz, et al.
Published: (2025)

Risk factors for development of diabetic foot ulcer disease in two large contemporary UK cohorts
by: Safoora Gharibzadeh, et al.
Published: (2025)

Association of semaglutide with less limb events in people with type 2 diabetes and peripheral artery disease or foot ulcers: An observational study comparing matched cohorts
by: Paola Caruso, et al.
Published: (2025)

Glycemic therapies and the risk of gastrointestinal adverse events in veterans with type 2 diabetes
by: Amara Sarwal, et al.
Published: (2025)

Fracture risk revisited: Bone mineral density T‐score and fracture risk in type 2 diabetes
by: V. Van Hulten, et al.
Published: (2024)

Metabolomic risk predictors of diabetic foot complications: A longitudinal observational study in type 1 diabetes
by: Jonas A. Andersen, et al.
Published: (2025)

Cost‐effectiveness of ON101 with general wound care for diabetic foot ulcers among patients with type 2 diabetes in Singapore: Analysis of a multi‐ethnic country in Asia
by: Hsuan‐Yu Su, et al.
Published: (2025)

Denosumab, for osteoporosis, reduces the incidence of type 2 diabetes, risk of foot ulceration and all‐cause mortality in adults, compared with bisphosphonates: An analysis of real‐world, cohort data, with a systematic review and meta‐analysis
by: Alex E. Henney, et al.
Published: (2024)

Cumulative risk of diabetic foot complications in risk groups of type 1 and type 2 diabetes: Real‐world evidence from a 22‐year follow‐up study
by: Abhilasha Akerkar, et al.
Published: (2025)

Type 2 diabetes genetic risk and incident diabetes across diabetes risk enhancers
by: Filipe A. Moura, et al.
Published: (2024)

Mortality patterns in Dutch diabetes outpatients
by: Jessica C. G. Bak, et al.
Published: (2024)

The potential for improved outcomes in the prevention and therapy of diabetic kidney disease through ‘stacking’ of drugs from different classes
by: David S. H. Bell, et al.
Published: (2024)

Incretin‐based therapies for individuals with obesity and heart failure with mildly reduced or preserved ejection fraction: A systematic review and meta‐analysis of randomized controlled trials
by: Thomaz Alexandre Costa, et al.
Published: (2025)

Partial remission of type 1 diabetes: Do immunometabolic events define the honeymoon period?
by: J. Jason Collier, et al.
Published: (2025)

Effect of semaglutide add‐on therapy for people living with type 1 diabetes and excess weight
by: Noga C. Minsky, et al.
Published: (2025)

Dose‐Escalation Regimens for Incretin Mimetics in Type 2 Diabetes Are Associated With Tolerance for Nausea and Vomiting
by: Michael A. Nauck, et al.
Published: (2026)

A Physiological Model of Incretin‐Based Therapies and Hierarchical Energy Allocation Across Metabolic Phenotypes
by: Christine Stier, et al.
Published: (2026)

Increased cardiovascular risk in people with LADA in comparison to type 1 diabetes and type 2 diabetes: Findings from the DPV registry in Germany and Austria
by: Rosa C. Golomb, et al.
Published: (2024)

Natriuretic peptide levels and predicting risk of developing new diabetes mellitus and metabolic syndrome
by: Jasraj Singh, et al.
Published: (2024)

Prediction of heart failure as the first major cardiovascular disease event in type 2 diabetes
by: Julian W. Sacre, et al.
Published: (2026)

Triglyceride variability and risk of heart failure events in type 2 diabetes: Results from the ACCORD trial
by: Daniel S. Nuyujukian, et al.
Published: (2025)

Work productivity, associated risk factors and costs on presenteeism and absenteeism in Chinese patients with young‐onset type‐2 diabetes in Hong Kong
by: Juliana N. M. Lui, et al.
Published: (2025)

Long‐acting insulin analogues and the risk of diabetic nephropathy among patients with type 2 diabetes: A population‐based cohort study
by: Julia Brillinger, et al.
Published: (2026)

Pre‐Treatment Concerns and Their Association With Functioning and Well‐Being During Incretin‐Based Therapy: A Cross‐Sectional Study
by: Ali Kapan, et al.
Published: (2026)

Fasting and postprandial kidney haemodynamic effects of empagliflozin and linagliptin in mono‐ and combination therapy compared to gliclazide in overweight people with type 2 diabetes ( RACELINES ): A randomised, double‐blind trial
by: Michaël J. B. van Baar, et al.
Published: (2025)

The effect of bolus advisors on glycaemic parameters in adults with diabetes on intensive insulin therapy: A systematic review with meta‐analysis
by: Elisabeth J. den Brok, et al.
Published: (2024)

Patients with type 1 diabetes are at elevated risk of developing new hypertension, chronic kidney disease and diabetic ketoacidosis after COVID ‐19: Up to 40 months’ follow‐up
by: Shiv Mehrotra‐Varma, et al.
Published: (2024)

Effect of tirzepatide on the risk of diabetic retinopathy in type 2 diabetes
by: Djordje S. Popovic, et al.
Published: (2024)

Metformin and risk of adverse pregnancy outcomes among pregnant women with gestational diabetes in the United Kingdom: A population‐based cohort study
by: Ya‐Hui Yu, et al.
Published: (2024)

Beyond glycated haemoglobin: Modelling contemporary management of type 2 diabetes with the updated Cardiff model
by: Phil McEwan, et al.
Published: (2025)

Long‐term outcomes of metabolic surgery versus medical/lifestyle therapy on metabolic dysfunction‐associated fatty liver disease in adults with obesity and type 2 diabetes
by: Michelle D. Lundholm, et al.
Published: (2024)

Lifetime and 10‐year cardiovascular risk prediction in individuals with type 1 diabetes: The LIFE‐T1D model
by: Marga A. G. Helmink, et al.
Published: (2024)

The pathophysiology, presentation and classification of Type 1 diabetes
by: Kristie I. Aamodt, et al.
Published: (2025)

Genomic risk prediction for type 2 diabetes in Australian individuals aged 70 years and older
by: Chenglong Yu, et al.
Published: (2025)

Could continuous subcutaneous glucose sensors ( CGMS ) be repurposed to diagnose diabetes in equivocal or challenging cases?
by: Martin B. Whyte, et al.
Published: (2025)

Risk of new‐onset diabetes and efficacy of pharmacological weight loss therapy
by: Filipe A. Moura, et al.
Published: (2024)

Genetic risk and polygenic risk score assessment of prediabetes and progression to type 2 diabetes
by: Usama Aliyu, et al.
Published: (2025)